Pharmacologic and nonpharmacologic thromboprophylactic strategies in atrial fibrillation

Area of Science:

• Cardiology
• Neurology
• Pharmacology

Background:

• Traditional stroke prevention in atrial fibrillation (SPAF) relied on aspirin and warfarin, guided by CHADS2 scoring.
• Many patients could not tolerate or use these therapies due to adverse events or contraindications.
• A paradigm shift is occurring with new SPAF strategies emerging.

Purpose of the Study:

• To systematically review emerging thromboprophylactic strategies for SPAF.
• To assess the comparative effectiveness of novel SPAF therapies.
• To review the advantages and disadvantages of mechanical, pharmacologic, and pharmacokinetic approaches.

Main Methods:

• Conducted an Ovid MEDLINE search from 1950 to present.
• Identified 15 randomized trials comparing thromboprophylactic drugs, devices, or procedures for SPAF.
• Reviewed specific mechanical, pharmacologic, and pharmacokinetic aspects of these strategies.

Main Results:

• New SPAF strategies include dual antiplatelet therapy, direct thrombin inhibition, factor Xa inhibition, and mechanical prophylaxis.
• Moderate to large clinical trials assess the comparative effectiveness of these emerging approaches.
• The review synthesizes findings from 15 randomized trials.

Conclusions:

• Emerging strategies offer promising alternatives for stroke prevention in atrial fibrillation.
• Comparative trials are crucial for understanding the effectiveness of novel SPAF therapies.
• A comprehensive review of mechanical, pharmacologic, and pharmacokinetic profiles is essential.